Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Vanucizumab Biosimilar - Anti-ANGPT2, VEGFA, mAb - Research Grade |
---|---|
Source | CAS 1448221-05-3 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Vanucizumab,RG-7221,RG7221,RO5520985,ANGPT2, VEGFA, ,anti-ANGPT2, VEGFA, |
Reference | PX-TA1355 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa |
Clonality | Monoclonal Antibody |
Vanucizumab has been investigated for the treatment of Colorectal Cancer and Advanced/Metastatic Solid Tumors.
Immobilized Human ANGPT2-Ang2 recombinant protein (cat. No. PX-P6245) at 0.5µg/mL (100µL/well) can bind Vanucizumab Biosimilar - Anti-ANGPT2, VEGFA, mAb (cat. No. PX-TA1355) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 105.6M.
Related products
Reviews
Il n’y a pas encore d’avis.